Glenmark Pharma's overactive bladder drug gets USFDA nod
According to IMS Health April 2017 sales data, the market for Vesicare tablets, 5 mg and 10 mg, saw annual sales of approximately USD 1.1 billion.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Overactive Bladder | Overactive Bladder Syndrome | Pharmaceuticals | VESIcare